Latest Insider Transactions at Alpine Immune Sciences, Inc. (ALPN)
This section provides a real-time view of insider transactions for Alpine Immune Sciences, Inc. (ALPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALPINE IMMUNE SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALPINE IMMUNE SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Christopher Peetz Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,900
-100.0%
|
-
|
|
May 20
2024
|
Robert E Conway Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
50,000
-100.0%
|
-
|
|
May 20
2024
|
Mitchell Gold Executive Chairman and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,245
-56.06%
|
-
|
|
May 20
2024
|
Stanford L Peng Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
344,163
-93.03%
|
-
|
|
May 20
2024
|
James Paul Rickey Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,961
-73.09%
|
-
|
|
May 20
2024
|
Remy Durand Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133,392
-88.31%
|
-
|
|
May 20
2024
|
Ulrich Martin Fuhs Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,120
-87.88%
|
-
|
|
May 18
2024
|
Peter A. Thompson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,680,496
-100.0%
|
-
|
|
May 18
2024
|
James N Topper Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,829,347
-100.0%
|
-
|
|
May 18
2024
|
Mitchell Gold Executive Chairman and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,627,157
-100.0%
|
-
|
|
May 18
2024
|
Xiangmin Cui Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,317,924
-100.0%
|
-
|
|
May 18
2024
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,680,496
-100.0%
|
-
|
|
May 08
2024
|
Remy Durand Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
95,288
+17.15%
|
$571,728
$6.36 P/Share
|
|
May 08
2024
|
Stanford L Peng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
271,792
+12.88%
|
$1,358,960
$5.98 P/Share
|
|
May 08
2024
|
Ulrich Martin Fuhs Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,820
+43.11%
|
$273,840
$12.07 P/Share
|
|
May 08
2024
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,245
+10.81%
|
$92,715
$7.55 P/Share
|
|
May 07
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,761
+7.15%
|
$187,327
$7.8 P/Share
|
|
Apr 25
2024
|
James N Topper Director |
SELL
Open market or private sale
|
Indirect |
19
-0.0%
|
$1,216
$64.57 P/Share
|
|
Apr 25
2024
|
James N Topper Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,200,000
+29.78%
|
-
|
|
Jan 26
2024
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
117,764
-100.0%
|
$2,708,572
$23.66 P/Share
|
|
Jan 26
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,764
+50.0%
|
$942,112
$8.91 P/Share
|
|
Jan 25
2024
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
236
-100.0%
|
$5,192
$22.0 P/Share
|
|
Jan 25
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+50.0%
|
$1,416
$6.51 P/Share
|
|
Jan 18
2024
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,234,636
+15.79%
|
$14,815,632
$12.74 P/Share
|
|
Jan 18
2024
|
Xiangmin Cui Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,234,636
+15.79%
|
$14,815,632
$12.74 P/Share
|
|
Jan 11
2024
|
Peter A. Thompson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
145,251
+5.67%
|
$1,743,012
$12.74 P/Share
|
|
Jan 11
2024
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
145,251
+5.67%
|
$1,743,012
$12.74 P/Share
|
|
Jan 04
2024
|
Remy Durand Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+45.02%
|
-
|
|
Jan 04
2024
|
James Paul Rickey Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+50.0%
|
-
|
|
Jan 04
2024
|
Stanford L Peng Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+39.88%
|
-
|
|
Jan 04
2024
|
Mitchell Gold Executive Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+50.0%
|
-
|
|
Dec 28
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
48,264
-1.8%
|
$917,016
$19.65 P/Share
|
|
Dec 28
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
74,441
+2.71%
|
$893,292
$12.74 P/Share
|
|
Dec 28
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,016
-100.0%
|
$20,320
$20.04 P/Share
|
|
Dec 28
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,016
+50.0%
|
$0
$0.65 P/Share
|
|
Dec 28
2023
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
1,364,849
-17.63%
|
$25,932,131
$19.07 P/Share
|
|
Dec 28
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
1,364,849
-17.63%
|
$25,932,131
$19.07 P/Share
|
|
Dec 27
2023
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
181,498
-4.45%
|
$3,448,462
$19.96 P/Share
|
|
Dec 27
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
181,498
-4.45%
|
$3,448,462
$19.96 P/Share
|
|
Dec 27
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
29,573
-100.0%
|
$591,460
$20.04 P/Share
|
|
Dec 27
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,573
+50.0%
|
$0
$0.65 P/Share
|
|
Dec 26
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
24,486
-100.0%
|
$489,720
$20.22 P/Share
|
|
Dec 26
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,486
+48.71%
|
$0
$0.55 P/Share
|
|
Dec 22
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
37,825
-100.0%
|
$756,500
$20.43 P/Share
|
|
Dec 22
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,825
+50.0%
|
$0
$0.45 P/Share
|
|
Dec 19
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
15,213
-100.0%
|
$289,047
$19.21 P/Share
|
|
Dec 19
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,213
+50.0%
|
$76,065
$5.02 P/Share
|
|
Dec 19
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
2,402
-100.0%
|
$48,040
$20.01 P/Share
|
|
Dec 19
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,402
+50.0%
|
$0
$0.45 P/Share
|
|
Dec 18
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
1,800
-100.0%
|
$34,200
$19.0 P/Share
|